MMP-13 Inhibitor Screening Kit (Fluorometric)

MILPITAS, Calif. - Jan. 25, 2021 - PRLog -- Matrix metalloproteinase-13 (MMP-13; Collagenase-3) is a zinc-dependent endopeptidase family member that is capable of degrading many protein components of the extracellular matrix (ECM) including type II collagen in articular cartilage and bone. It is produced and secreted as a 60-kDa inactive, precursor form (proMMP-13), which is activated to a 48-kDa form by extracellular proteinases such as plasmin, MMP-2, MMP-3 and MMP-14. MMP-13 has wide substrate specificity, as it degrades collagen types (I-IV) but preferentially hydrolyzes type II collagen.

Additionally, it cleaves other ECM molecules including fibronectin, aggrecan, osteonectin etc. MMP-13 plays a major role in ECM remodeling during fetal bone development, post-natal bone remodeling, tissue remodeling etc. It is overexpressed in numerous pathological conditions including rheumatoid arthritis, osteoarthritis, atherosclerosis, aortic aneurysms, cancer etc. Thus, developing and screening of selective MMP-13 inhibitors is under intensive investigation for therapeutic intervention.

BioVision's MMP-13 Inhibitor Screening Assay Kit provides a quick, easy and sensitive assay for screening, studying and characterizing potential inhibitors of MMP-13. In this assay, MMP-13 hydrolyzes a FRET-based MMP-13 substrate and releases unquenched by the catalysis of fluorescent group, Mca, which is detected fluorometrically at Ex/Em = 325/393 nm. A potent, specific MMP-13 inhibitor is also included in the kit.

Figure: Inhibition of MMP-13 activity by the MMP-13 inhibitor (BioVision Cat. # 9607). IC50 was calculated to be 100.4 nM. Assay was performed following the kit protocol.

For more information on this Assay Kit Cat# K2067, Visit: https://bit.ly/39hLyOR